BAFF may modulate the rate of B-cell repopulation after rituximab therapy for acute renal transplant rejection.
Zarkhin
Valeriya
V
Li
Li
L
Sarwal
Minnie M
MM
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D053264:B-Cell Activating Factor / Q000502:physiology*; D001402:B-Lymphocytes / Q000187:drug effects / Q000276:immunology*; D002470:Cell Survival / Q000276:immunology; D006084:Graft Rejection / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D016030:Kidney Transplantation / Q000276:immunology*; D008212:Lymphocyte Depletion; D000069283:Rituximab
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D053264:B-Cell Activating Factor; D007166:Immunosuppressive Agents; C505719:TNFSF13B protein, human; D000069283:Rituximab